If you have been reading about incretin mimetic and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
In 1389 the Bishop of Troyes sent a memorial to Antipope Clement VII, declaring that the cloth had been "artificially painted in an ingenious way" and that "it was also proved by the artist who had painted it that it was made by human work, not miraculously produced". In 1390 Clement VII consequently issued four papal bulls, with which he allowed the exposition, but ordered to "say aloud, to put an end to all fraud, that the aforementioned representation is not the true Shroud of Our Lord Jesus Christ, but a painting or panel made to represent or imitate the Shroud". However, in 1506 Pope Julius II reversed this position and permitted the faithful who believe the Shroud to be authentic to venerate it as such, authorizing the public veneration of it with its own mass and office. The Vatican newspaper L'Osservatore Romano covered the story of Secondo Pia's photograph of 28 May 1898 in its edition of 15 June 1898, but it did so with no comment and thereafter Church officials generally refrained from officially commenting on the photograph for almost half a century. The first official modern association between the Shroud and the official Catholic Church dates from 1940, when Sister Maria Pierina De Micheli approached the curia of Milan requesting authorization to produce a devotional medal based on the image of Jesus's face from the Shroud. This "Holy Face Medal" was approved by Pope Pius XII and it was initially used as a means of protection during the Second World War.
=== Genome === Chinese scientists published a draft genome of Ginkgo biloba in 2016. The tree has a large genome of 10.6 billion DNA nucleobase "letters" (the human genome has three billion) and about 41,840 predicted genes which enable a considerable number of antibacterial and chemical defense mechanisms. 76.58% of the assembled sequence turned out to be repetitive sequences. In 2020, a study in China of ginkgo trees up to 667 years old showed little effects of aging, finding that the trees continued to grow with age and displayed no genetic evidence of senescence, and continued to make phytochemicals indefinitely.
The Purine Nucleotide Cycle is a metabolic pathway in protein metabolism requiring the amino acids aspartate and glutamate. The cycle is used to regulate the levels of adenine nucleotides, in which ammonia and fumarate are generated. AMP converts into IMP and the byproduct ammonia. IMP converts to S-AMP (adenylosuccinate), which then converts to AMP and the byproduct fumarate. The fumarate goes on to produce ATP (energy) via oxidative phosphorylation as it enters the Krebs cycle and then the electron transport chain. Lowenstein first described this pathway and outlined its importance in processes including amino acid catabolism and regulation of flux through glycolysis and the Krebs cycle. AMP is produced after strenuous muscle contraction when the ATP reservoir is low (ADP > ATP) by the adenylate kinase (myokinase) reaction. AMP is also produced from adenine and adenosine directly; however, AMP can be produced through less direct metabolic pathways, such as de novo synthesis of IMP or through salvage pathways of guanine (a purine) and any of the purine nucleotides and nucleosides. IMP is synthesized de novo from glucose through the pentose phosphate pathway which produces ribose 5-P, which then converts to PRPP that with the amino acids glycine, glutamine, and aspartate (see Purine metabolism) can be further converted into IMP.
Sources: en.wikipedia.org
=== Post mortem or in tissue biopsies === Amyloid beta can be measured semiquantitatively with immunostaining, which also allows one to determine location. Amyloid beta may be primarily vascular, as in cerebral amyloid angiopathy, or in amyloid plaques in white matter. One sensitive method is ELISA which is an immunosorbent assay which utilizes a pair of antibodies that recognize amyloid beta. Atomic force microscopy, which can visualize nanoscale molecular surfaces, can be used to determine the aggregation state of amyloid beta in vitro. Vibrational microspectroscopy is a label-free method that measures the vibration of molecules in tissue samples. Amyloid proteins like Aβ can be detected with this technique because of their high content of β-sheet structures. Dual polarisation interferometry is an optical technique which can measure early stages of aggregation by measuring the molecular size and densities as the fibrils elongate. These aggregate processes can also be studied on lipid bilayer constructs.
For his contributions to the development and progress of Malaysia, Mahathir was honoured by his successor, Abdullah Badawi, with the title Bapa Pemodenan Malaysia (Father of Malaysia's Modernisation) after stepping down from office. The following year, Barisan Nasional leaders and members paid tribute to Mahathir during a dinner in Kuala Lumpur, acknowledging his remarkable contributions to the coalition and the nation.
In a retail market that is decriminalized such as in The Netherlands, where wholesale production is illegal but prosecutions are not always enforced because of the contradiction of the law that is recognised by the courts, competition puts pressure on breeders to create increasingly attractive varieties to maintain market share. Breeders give their strains distinct and memorable names in order to help differentiate them from their competitors' strains, although they may in fact be very similar.
Due to the wide range of causes of camptocormia, there is no one treatment that suits all patients. In addition, there is no specific pharmacological treatment for primary BSS. The use of analgesic drugs depends entirely on the intensity of the back pain. Muscular-origin BSS can be alleviated by positive lifestyle changes, including physical activity, walking with a cane, a nutritious diet, and weight loss. Worsening of symptoms is possible but rare in occurrence. Treatment of the underlying cause of the disease can alleviate the condition in some individuals with secondary BSS. Other treatment options include drugs, injections of botulinum toxin, electroconvulsive therapy, deep brain stimulation, and surgical correction. Unfortunately, many of the elderly individuals affected by the BSS are not treated surgically due to age-related physical ailments and the long postoperative recovery period.
Sources: en.wikipedia.org
==== Privatization of waterways in the North, Recife Metro and COMPESA ==== In June 2025, the Lula government, despite strong popular opposition, supported the privatization of the Recife Metro and of the COMPESA (the Pernambuco sanitation company responsible for water supply in the state), measures announced by the governor of Pernambuco, Raquel Lyra. In both cases, the BNDES, under the leadership of Aloizio Mercadante, organized the studies to make the privatization process feasible and will also conduct the bidding procedures. In late May, the chief of staff, Rui Costa, had already confirmed that the Recife Metro would be privatized, continuing a process initiated in 2019 during the Jair Bolsonaro administration. The argument used by the government to justify the measure is that the metro system generates only financial losses. The decision prompted protests in Pernambuco, especially in Recife. In addition, in September 2025 the government included the waterway of the Madeira River and the waterways of the Tocantins and Tapajós rivers in the National Privatization Program (PND), a measure that also received criticism. During the 2022 presidential campaign and in government, Lula strongly criticized the privatizations carried out by the previous administration and even promised that the Recife Metro would not be privatized. The privatization measures were criticized especially by the more radical sectors of the Brazilian left, which also criticized the government's attempt to soften the term “privatization” by presenting them as “concessions”.
=== Post-translational modifications === C3orf62 possesses two post-translational modifications, both are phosphorylation sites with locations at amino acid 210 and 224. A natural variant is found at amino acid 110 (Glutamic acid (E)--> Lysine K). It appears as though C3orf62 may have a YinOYang site at residue 115, meaning that this Threonine residue is predicted to be O-GlycNAcylated as well as phosphorylated. This site may be reversibly and dynamically modified by O-GlcNAc or Phosphate groups at different times in the cell.
Laser-based ambient ionization is a two-step process in which a pulsed laser is used to desorb or ablate material from a sample and the plume of material interacts with an electrospray or plasma to create ions. Lasers with ultraviolet and infrared wavelengths and nanosecond to femtosecond pulse widths have been used. Although atmospheric pressure MALDI is performed under ambient conditions, it is not generally considered to be an ambient mass spectrometry technique. Laser ablation was first coupled with mass spectrometry in the 1980s for the analysis of metals using laser ablation inductively coupled plasma mass spectrometry (LA-ICPMS). The laser ablates the sample material that is introduced into an ICP to create atomic ions.
Radiation Source Use and Replacement: Abbreviated Version. National Academies Press. ISBN 978-0-309-11014-3. O'Neil, Marydale J.; Heckelman, Patricia E.; Roman, Cherie B., eds. (2006). The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals (14th ed.). Merck Research Laboratories, Merck & Co. ISBN 978-0-911910-00-1. Osborne-Lee, I. W.; Alexander, C. W. (1995). "Californium-252: A Remarkable Versatile Radioisotope". Oak Ridge Technical Report ORNL/TM-12706. doi:10.2172/205871. OSTI 205871. Ruiz-Lapuente, P.; Canal, R.; Isern, J. (1996). Thermonuclear Supernovae. Springer Science+Business Media. ISBN 978-0-7923-4359-2. Seaborg, Glenn T.; Loveland, Walter D. (1990). The Elements Beyond Uranium. John Wiley & Sons, Inc. ISBN 978-0-471-89062-1. Seaborg, Glenn T. (1994). Modern alchemy: selected papers of Glenn T. Seaborg. World Scientific. ISBN 978-981-02-1440-1. Seaborg, Glenn T. (1996). Adloff, J. P. (ed.). One Hundred Years after the Discovery of Radioactivity. Oldenbourg Wissenschaftsverlag. ISBN 978-3-486-64252-0. Seaborg, Glenn T. (2004). "Californium". In Geller, Elizabeth (ed.). Concise Encyclopedia of Chemistry. McGraw-Hill. p. 94. ISBN 978-0-07-143953-4. Szwacki, Nevill Gonzalez; Szwacka, Teresa (2010). Basic Elements of Crystallography. Pan Stanford. ISBN 978-981-4241-59-5. Walker, Perrin; Tarn, William H., eds. (1991). Handbook of Metal Etchants. CRC Press. ISBN 978-0-8493-3623-2. Weeks, Mary Elvira; Leichester, Henry M. (1968). "21: Modern Alchemy". Discovery of the Elements. Journal of Chemical Education. pp. 848–850. ISBN 978-0-7661-3872-8.
==== United States ==== In March 2020, the FDA changed the regulatory pathway for approval of new insulin products. Insulin is regulated as a biologic rather than as a drug. The changed status gives the FDA more flexibility for approval and labeling. In July 2021, the FDA approved insulin glargine-yfgn (Semglee), a biosimilar product that contains the long acting analog insulin glargine. Insulin glargine-yfgn is interchangeable and less expensive than the reference product, insulin glargine (Lantus), which had been approved in 2000. The FDA requires that new insulin products are not inferior to existing insulin products with respect to reduction in hemoglobin A1c.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.